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Ubiquitin is a versatile post-translational 
modification which is covalently attached to 
protein targets either as a single moiety or as 
a ubiquitin chain. In contrast to K48 and K63-
linked chains which have been extensively 
studied, the regulation and function of most 
atypical ubiquitin chains is only starting to 
emerge. The deubiquitinase 
TRABID/ZRANB1 is tuned for the recognition 
and cleavage of K29 and K33-linked chains. 
Yet, substrates of TRABID and the cellular 
functions of these atypical ubiquitin signals 
remain unclear. We determined the 
interactome of two TRABID constructs 
rendered catalytic dead either through a point 
mutation in the catalytic cysteine residue or 
through removal of the OTU catalytic domain. 
We identified 50 proteins trapped by both 
constructs and which therefore represent 
candidate substrates of TRABID. We then 
validated the E3 ubiquitin ligase HECTD1 as a 
substrate of TRABID and used UbiCREST 
and Ub-AQUA proteomics to show that 
HECTD1 preferentially assembles K29- and 
K48-linked ubiquitin chains. Further in vitro 
autoubiquitination assays using ubiquitin 
mutants established that while HECTD1 can 
assemble short homotypic K29 and K48-
linked chains, it requires branching at K29/K48 
in order to achieve its full ubiquitin ligase 
activity. We next used transient knockdown 
and genetic knock out of TRABID in 
mammalian cells in order to determine the 
functional relationship between TRABID and 
HECTD1. This revealed that upon TRABID 
depletion, HECTD1 is readily degraded. Thus, 
this study identifies HECTD1 as a mammalian 
E3 ligase which assembles branched K29/K48 
chains and also establishes TRABID-HECTD1 
as a DUB/E3 pair regulating K29 linkages. 
Introduction 
Ubiquitin is a small and highly conserved 
protein modifier which has emerged as a 
complex yet specific post-translational 
modification regulating protein fate and 
function. The role of ubiquitin is central to 
proteostasis by serving as the key signal for 
the degradation of proteins or organelles 
whether it be through the Ubiquitin 
Proteasome System (UPS) or autophagy (1-
3). Ubiquitin is added to lysine residues on 
protein targets through the sequential activity 
of E1-activating enzymes, E2-conjugating 
enzymes and E3 ubiquitin ligases, as a single 
moiety or as a ubiquitin chain (4,5). These 
distinct signals mediate specific and diverse 
downstream cellular processes. For example, 
while addition of a single ubiquitin molecule on 
a protein substrate can regulate its trafficking, 
polyubiquitination regulates a plethora of 
cellular processes including cell cycle 
progression, DNA repair and inflammation (6-
9). Polyubiquitin chains are assembled 
through an isopeptide bond between the C-
terminus of Gly76 of a donor ubiquitin and the 
a-amino group of any of the seven lysines (K6, 
K11, K27, K29, K33, K48 and K63) or the N-
terminus (i.e., linear ubiquitin, Met-1) of an 
acceptor ubiquitin. Protein ubiquitination also 
occurs on non-canonical attachment sites 
within substrates, including on serine, 
threonine, and cysteine residues (10-12). 
Some deubiquitinases (DUB), in particular 
those from the Ovarian Tumour (OTU) family, 
and E3 ubiquitin ligases such as members of 
the Homologous to the E6AP carboxyl 
terminus (HECT) family have shown 
specificity for particular ubiquitin chains. This, 
combined with the difference in the three-
dimensional structure of these ubiquitin 
polymers, further suggests that they represent 
distinct signals (13). All ubiquitin linkage types 
have been identified in yeast (14) and 
mammalian cells (15). While homotypic K48-
linked polyubiquitin chains target proteins for 
degradation by the UPS, cargoes modified 
with K63-linked chains are recognised as part 
of the autophagic response (16-18). 
Nevertheless, the role and function of 
polyubiquitin chains beyond those assembled 
through homotypic (i.e., assembled through 
one lysine only) such as K48 and K63 
linkages, is only starting to emerge (19-21). 
More recently, polyubiquitin has been found to 
exist as heterotypic and also branched chains. 
For example, branched K11/K48-linked chains 
increase the degradation rate of mitotic cyclins 
by the UPS, while branched K48/K63 chains 
regulate NF-kB gene activation through 
recognition by TAB2, a subunit of the TAK1 
complex (22,23). 
TRABID (also known as ZRANB1), belongs to 
OTU DUB family (24). It contains three highly 
conserved Npl14 zinc finger domains (3xNZF) 
which function as ubiquitin binding domains 
(UBD), and the OTU catalytic domain 
responsible for the hydrolysis of ubiquitin 
polymers (24-26). The expansion of the 
ubiquitin toolbox through for example the 
chemical synthesis of ubiquitin dimers, has 
been instrumental in determining TRABID’s 















Further analysis using the full set of eight 
ubiquitin dimers revealed that in addition to 
K29-linked ubiquitin dimers, TRABID also 
cleaves K33-linked ubiquitin chains and that 
the activity towards K29 and K33-linked 
dimers is greater than for K63-linked 
diubiquitin (28). The discovery of the AnkUBD 
as a novel UBD abutting the N-terminus of 
TRABID OTU domain, revealed that it is 
required for full DUB activity, and to some 
extent specificity too. These findings as well as 
recent studies which identified TRABID’s NZF 
1 as the minimal UBD required for the 
recognition of K29- and K33-linked diubiquitin 
establish TRABID as a unique DUB highly 
tuned for the recognition and processing of 
these atypical ubiquitin chains (29-31). 
TRABID has been proposed to regulate the 
Wnt/b-catenin/Tcf signaling pathway through 
APC (Adenomatous Polyposis Coli), the 
epithelial to mesenchymal transition (EMT) 
through Twist, as well as the innate immune 
response, with these studies implicating the 
deubiquitination of K63-linked chains as 
potential mechanism (32-35). More recently, 
TRABID was shown to process K29 and K33-
linked chains on UVRAG, a Beclin 1 complex 
component, thereby inhibiting autophagy and 
increasing hepatocellular cellular carcinoma 
growth (36). Another interesting finding came 
through phenotypic studies of Trabid KO mice 
which revealed that in dendrocytes, Trabid 
loss-of-function led to proteasomal 
degradation of the histone demethylase Jmjd2 
(37). This in turn decreased expression of 
proinflammatory cytokines interleukin 12 and 
23 and dampened inflammatory T-cell 
responses. The histone methyltransferase 
EZH2 also appears to be a target of TRABID 
DUB activity, and TRABID depletion has been 
shown to decrease EZH2 levels (38). These 
studies highlight a role for TRABID in 
transcriptional regulation as well as novel 
crosstalk between protein ubiquitination and 
epigenetics mechanisms although the types 
and composition of ubiquitin chains involved 
remain to be determined.  
Proteomics studies have been useful in 
identifying TRABID candidate interactors 
including components of the Striatin-
Interacting Phosphatase and Kinase 
(STRIPAK) complex and the E3 ubiquitin 
ligases HECTD1 and HERC2 (33,39). Yet 
whether these proteins represent substrates 
of TRABID DUB activity rather than interactors 
has remained unclear. In this study, we aimed 
to further expand on our understanding of 
TRABID as well as the atypical ubiquitin 
chains which it regulates. We first used two 
catalytic dead TRABID constructs, a single 
point mutation in the catalytic OTU domain 
(TRABIDC443S) and a construct lacking the 
OTU domain entirely (TRABID DOTU), to 
specifically trap ubiquitinated substrates. By 
comparing the interactome of these two 
constructs, we identified NZF- and OTU-
specific TRABID interactors, including several 
E3 ubiquitin ligases as candidate interactors 
and potential substrates of TRABID DUB 
activity. We validated HECTD1 as a substrate 
of TRABID activity and used in vitro 
autoubiquitination assays, Ubiquitin Chain 
Restriction Analysis (UbiCREST) and 
Ubiquitin-Absolute QUAntification (Ub-AQUA) 
to show that the catalytic HECT domain of 
HECTD1 preferentially assembles K29- and 
K48-linked ubiquitin chains. Interestingly, our 
data indicate that although UBE3C and 
HECTD1 both use K29 and K48 linkages to 
assemble ubiquitin chains, the topology of the 
chains is different. Indeed, we found that to 
achieve its full activity, HECTD1 assembles 
ubiquitin chains which contain branched 
K29/K48 linkages. Finally, we explored the 
functional relationship between TRABID and 
HECTD1 using transient siRNA knockdown as 
well as CRISPR/Cas9 TRABID knockout in 
mammalians cells and mice. Loss-of-function 
and rescue assays showed that TRABID 
stabilises HECTD1 protein levels, further 
establishing this novel and functional DUB-E3 
pair as key regulators of K29-linked 
polyubiquitination 
Results 
Interactome studies of two catalytic dead 
TRABID constructs differentiates between 
OTU-specific interactors and candidate 
substrates 
TRABID is highly tuned for recognising and 
processing K29 and K33 ubiquitin linkages. 
Yet, most cellular mechanisms reported to 
date have implicated a K63-specific DUB 
activity. To explore this further, we analysed 
the interactome of two catalytic dead TRABID 
constructs following transient expression in 
HEK293ET cells (Fig 1A-C). Both 
TRABIDC443S and TRABID DOTU are 
catalytically inactive but can still efficiently trap 
ubiquitin through the ubiquitin binding property 
of the NZF domains (32,33). To validate this, 
we used immunoprecipitation assays and a 















previously used as a readout to visualise 
polyubiquitin trapped by catalytic dead 
TRABID in cells (Supplementary Fig 1A-C) 
(28,31,32). Point mutations (TY to LV) in each 
of the NZF domains reduced ubiquitin trapping 
as shown by a reduced ubiquitin smear and 
complete loss of puncta formation 
(Supplementary Fig 1B & C, respectively) 
(25,32). Together, this data confirms that loss 
of TRABID DUB activity results in the trapping 
of ubiquitinated species, visualised as puncta 
in cells, and this requires functional NZFs. 
Although a minimal construct consisting of 
TRABID NZF 1-3 (AA1-200) should in theory 
suffice to trap ubiquitin, such a construct was 
less efficient in both our trapping 
immunoprecipitation and puncta formation 
assays. This likely reflects the additional 
contribution of AnkUBD in enhancing ubiquitin 
trapping (28). 
By comparing the interactome of TRABIDC443S 
to that of TRABID DOTU, we aimed to 
differentiate between bona fide substrates and 
interactors since it is the NZF domains and not 
the OTU domain, which mediate substrate 
recognition. 3xFLAG_empty vector (Ev), 
3xFLAG_full-length-TRABIDC443S and 
3xFLAG_TRABID DOTU were transiently 
expressed in HEK293ET cells, 
immunoprecipitated with FLAG® M2 magnetic 
beads, followed by LC-MS/MS analysis on an 
Orbitrap (Supplementary Fig 1D). The initial 
list included 2,225 proteins with at least 2 
unique peptides in either TRABID 
interactomes, and zero unique peptide in the 
empty vector control condition 
(Supplementary Table 1). Our working list 
included 23 proteins exclusive to 
3xFLAG_TRABID DOTU and 103 proteins 
exclusive to full-length 3xFLAG_TRABIDC443S. 
Nearly all the components of the STRIPAK 
complex including Striatin 3, 
CTTNBP2/CTTNBP2L, SLMAP and 
FAM40A/FAM40B, were identified in the 
3xFLAG-full-length-TRABIDC443, but not the 
3xFLAG_TRABID DOTU condition. Although 
this kinase/phosphatase complex had already 
been identified in the original full-length 
TRABIDWT interactome, our data now show 
that the interaction between STRIPAK and 
TRABID is primarily mediated by the catalytic 
OTU domain rather than the ubiquitin binding 
properties of TRABID NZF (Fig 1B & C) (39). 
We also identified 50 proteins common to both 
3xFLAG_TRABID DOTU and 3xFLAG_ FL 
TRABIDC443S (Supplementary Table 1) and 
therefore reasoned that this list likely 
represented direct substrates of TRABID DUB 
activity. DUBs often exist as part of protein 
complexes which can include other DUBs as 
well as E3 ubiquitin ligases and we found both 
classes of enzymes in our candidate 
substratome list (Fig 1B & C; Supplementary 
Table 1) (40). The identification of the E3 
ubiquitin ligase HECTD1 as a candidate 
substrate of TRABID had been previously 
suggested (33,39). However, the nature of this 
interaction remained puzzling given that 
HECTD1 has been suggested to assemble 
K63-linked chains, while TRABID 
preferentially recognises and cleaves K29 and 
K33 linkages. Therefore, we further explored 
the TRABID-HECTD1 interaction in order to 
reconcile and also expand on these 
observations. First, we determined whether 
the trapping of E3 ubiquitin ligases by catalytic 
dead TRABID was dependent on ubiquitin. 
For this, we immunoprecipitated the indicated 
endogenous HECT ligases from HEK293ET 
cells overexpressing 3xFLAG_TRABID DOTU 
or 3xFLAG_TRABID DOTUTY>LV, a ubiquitin 
binding deficient mutant (Fig 1D & 2A). We 
chose HECTD1, TRIP12, UBE3C, HERC2, 
since these had the highest number of unique 
peptides identified in our pull-down LC/MS-MS 
experiments. NEDD4 was used as negative 
control since it was not identified in any of our 
interactome studies. Endogenous HECTD1 
and HERC2 could both be 
immunoprecipitated by the trapping construct 
3xFLAG_TRABID DOTU and this interaction 
required functional NZFs since the TY>LV 
mutant abrogated these interactions (Fig 1D). 
In contrast, we could not validate TRIP12 or 
UBE3C as interactors/substrates trapped by 
catalytic dead TRABID although this could 
reflect the abundance and or expression 
pattern of these E3s. For instance, TRIP12 
has been shown to primarily localise to the 
nucleus and its low recovery in our 
immunoprecipitation assay could be due to the 
lysis buffer used. 
HECTD1 is a substrate of TRABID DUB 
activity 
We next used immunoprecipitation assays to 
show that FL TRABIDC443S indeed traps higher 
molecular weight species corresponding to 
ectopically expressed full-length mouse 
Hectd1 (Fig 1E, lane 8, Hectd1HMW). In 
contrast, in the condition where TRABID is 
active (Fig 1E, lane 5), or if catalytic dead FL 















Hectd1MW species were markedly reduced. 
This suggests that catalytic dead TRABID 
traps higher molecular weight species of 
Hectd1 and that these species are dependent 
upon the ubiquitin ligase activity of Hectd1. We 
obtained similar data when switching 3xFLAG 
and EGFP tags around (Supplementary Fig 
1E). Conjointly, this indicates that TRABID 
regulates Hectd1 autoubiquitination in cells. 
Importantly, these observations held true for 
endogenous HECTD1 (Fig 2). By using 
deletion constructs in immunoprecipitation 
experiments, we found that TRABID NZF 1-3 
is required for its interaction with endogenous 
HECTD1 (Fig 2A & B). In fact, with increased 
exposure of the membrane, we were able to 
detect endogenous HECTD1HMW species 
trapped by TRABID DOTU, FL-TRABIDC443S 
and to a lesser extent TRABID NZF 1-3 (Fig 
2C, lanes 2, 4, 6). Importantly, HECTD1HMW 
could not be trapped by the corresponding 
NZF TY>LV mutants, nor by active/wild type 
TRABID (Fig 2C, lanes 3, 5, 7 and 8). Further 
mapping using 3xFLAG-tagged and EGFP-
tagged TRABID NZF constructs narrowed 
down the minimal domains involved as NZF 1 
+ 2 (Fig 2D). Since individual TRABID NZF 
constructs expressed better when GFP 
tagged, we repeated the immunoprecipitation 
assay shown in Fig 2E with these constructs 
and identified NZF 1 has the minimal domain 
mediating interaction with endogenous 
HECTD1 (Fig 2F, lane 3). This is important 
since TRABID NZF 1 is a K29/K33-specific 
UBD (29-31). 
Although we attempted to validate the 
interaction between endogenous TRABID and 
endogenous HECTD1, none of the four 
TRABID antibodies which we tried could 
detect endogenous TRABID (Data not 
shown). As an alternative approach, we 
further validated this interaction using 
recombinantly expressed GST-tagged 
TRABID NZF 1-3 as bait (Fig 3A). GST-
TRABID NZF 1-3, but not its ubiquitin binding 
deficient mutant GST-TRABID NZF 1-3TY>LV 
nor GST alone, could enrich for high molecular 
weight ubiquitin chains as well as endogenous 
HECTD1 (Fig 3A, lane 3). Since HERC2 was 
also found to potentially interact with catalytic 
dead TRABID, we further validated the IP data 
shown in Fig 1D more stringently, by including 
an IgG control IP. Rabbit IgG, HECTD1 or 
HERC2 were coupled to magnetic 
Dynabeads® and used in immunoprecipitation 
assays using lysates from HEK293ET 
overexpressing either 3xFLAG_FL 
TRABIDC443S or an empty vector control (Fig 
3B). Although immunoprecipitation of 
endogenous HECTD1 led a clear detection of 
3xFLAG_FL TRABIDC443S, we observed a 
similar signal between the IgG control IP and 
the endogenous HERC2 IP. This is perhaps 
not surprising given that the membrane had to 
be overexposed in Fig 1D to enable HERC2 
detection. GST-TRABID NZF 1-3 pulldown 
showed a faint signal for HERC2 further 
suggestive of a very weak interaction (Fig 3A). 
HECTD1 assembles K29 and K48-linked 
ubiquitin chains 
DUBs and E3s have been shown to function 
as enzyme pairs, either  regulating a particular 
cellular process, each other’s stability, and/or 
activity (40). For example: the DUB BRCC36 
together with the RING E3 ligase BRCA1 
regulate the DNA damage response; the RBR 
E3 ligase Parkin and the DUB USP30 
contribute to mitophagy; the DUB Ubp2 can 
impede yeast growth by antagonising the 
function of the HECT E3 Rsp5; the DUB 
FAM/USP9x interacts with and stabilises 
SMURF1 and this impacts on cell motility (41-
43). Therefore, we further explored the 
molecular basis for the TRABID-HECTD1 
interaction and hypothesised that HECTD1 
could assemble ubiquitin chains that are 
subject to TRABID DUB activity. This implied 
that HECTD1 was modified, perhaps through 
autoubiquitination, with K29- and/or K33-
linked chains given these are preferentially 
recognised by TRABID NZF 1 (29-31). 
Determining the type and composition of 
ubiquitin chains on protein targets in cells has 
proved to be challenging. Therefore, we 
exploited the property of C-terminal HECT 
domains to autoubiquitinate in vitro in the 
absence of a substrate as a proxy for 
determining HECTD1 ubiquitin ligase 
specificity (Fig 4) (44,45). We previously 
identified UBE2D1, 2 and 3 as HECTD1’s 
cognate E2s, while UBE2L3 showed little if 
any cooperativity for polyubiquitin chain 
assembly (46). We now further expand this 
analysis to a set of E2s including UBE2H3, 
UBE2R1, UBE2E1, UBE2L6 and UBE2C (Fig 
4A). Although UBE2L3, UBE2L6 and UBE2C 
seemed competent in priming GST-HECTDCD 
with one ubiquitin molecule as shown by the 
monoubiquitinated GST-HECTDCD signal, 
there was weak HECTD1 ligase activity as 
indicated by a faint ubiquitin smear (Fig 4A, 
lanes 10-12). This suggests that in contrast to 















ubiquitin chains on HECTD1 (Fig 4A, lanes 6-
8), UBE2L3, UBE2L6 and UBE2C can only 
prime HECTD1 with a single ubiquitin moiety 
only. In contrast, UBE2H3 and UBE2R1 
showed no cooperation with HECTD1 ligase 
activity as (Fig 4A, lanes 4 and 5). Specific E2-
E3 cooperativity has been reported for other 
HECT ligases (47). The best example for E2-
E3 cooperativity in cells is in the context of 
mitosis where UBE2C assembles short chains 
on mitotic cyclins prior to their elongation with 
K11-linked chains via UBE2S (48-50). A 
recent report further addressed the molecular 
basis for E2-E3 cooperativity in the context of 
ERAD RING E3 ligases Doa10 and Hrd1 
which have distinct preferences for Ubc6 and 
7 for priming, but not for chain elongation (51). 
Some E2 conjugating enzymes have also 
been shown to drive ubiquitin transfer onto 
free lysine residues independently of E3 
activity and this is particularly relevant for 
substrates which contain a ubiquitin binding 
domain (52,53). For instance, UBE2D3~Ub 
reacts with free lysine and cysteine residues, 
whereas UBE2L3~Ub only reacts with 
cysteines (54). Although this mechanism of 
E3-independent ubiquitin transfer is more 
relevant for RING E3 ligases, we nevertheless 
validated that the activity we observed in our 
assay was due to the catalytic HECT domain 
specifically. Indeed, a point mutation in the 
catalytic cysteine residue (C2579G or 
C2579A) abrogated HECTD1 ligase activity 
(Fig 4B). To further ascertain that the 
observed HECTD1 ligase activity represents 
autoubiquitination, we next tested whether it 
occurred in cis or trans. For this, we tested 
whether wild-type His6-HECTD1CD could 
ubiquitinate catalytic dead GST-HECTDCD 
(C2579G or C2579A). However, we found that GST-
HECTDCD catalytic mutants were not 
polyubiquitinated in the presence of active 
His6-HECTD1CD (Fig 4C, Anti-GST blot, lanes 
5 and 6). This indicates that autoubiquitination 
of HECTDCD occurs in cis. 
We next used in vitro autoubiquitination 
assays and ubiquitin mutants to determine the 
type of ubiquitin chains preferentially 
synthesized by HECTD1 (Fig 4D). Ubiquitin, 
either methylated at all Lys (i.e., UbMet) or 
mutated at all lysine residues into arginine 
(UbK0), was used as control to reveal multi-
monoubiquitination events on GST-
HECTD1CD. In contrast to ubiquitin WT, which 
showed the full extent of ubiquitin chains 
synthesized by HECTD1 (Fig 4D, lane 6), both 
UbMet and UbK0 showed distinct bands 
indicative of multi-monoubiquitination (Fig 4D, 
lanes 4 and 5, respectively). Ubiquitination 
assays with ubiquitin Konly mutants, which 
have all, but the indicated lysine mutated to 
arginine, were then used to reveal HECTD1 
specificity in terms of the linkages utilized to 
assemble ubiquitin chains. Using ubiquitin 
K27only, K33only or K63only mutants led to 
autoubiquitination patterns similar to the multi-
monoubiquitination controls. In contrast, 
UbK29only and UbK48only showed ubiquitin smears 
corresponding to polyubiquitinated HECTD1 
(Fig 4D, lanes 10 and 12). However, neither 
UbK29only nor UbK48only recapitulated the full 
smear obtained with UbWT, suggesting that 
HECTD1 might assemble mixed K29- and 
K48-linked ubiquitin chains (Fig 4D, lanes 10 
and 12 vs. 6). 
To further validate the requirement for K29 
and K48 linkages for ubiquitin chain assembly 
by HECTD1, autoubiquitination assays were 
carried out using K/R ubiquitin mutants, which 
have only the indicated lysine residue mutated 
to arginine. In the presence of UbK29R, ubiquitin 
chain formation was markedly reduced (Fig 
4E, lane 7 vs. 6). In contrast, UbK48R had a 
marginal effect on the ubiquitin smear (Fig 4E, 
lane 8 vs. 6). This indicates that K29 rather 
than K48 is the likely prime linkage used by 
HECTD1 to assemble the core of the 
polyubiquitin chains we observed.  
Quantitative linkage analysis of ubiquitin 
chains assembled by HECTD1 
To determine the linkage composition of 
ubiquitin chains assembled by HECTD1 with 
more precision, we carried out UbiCREST and 
ubiquitin-Absolute QUAntification (Ubiquitin-
AQUA) on in vitro autoubiquitinated GST-
HECTD1CD (Fig 5) (15,55-57). 
Polyubiquitinated GST-HECTD1CD was 
incubated with the indicated linkage-specific 
DUBs for 5, 30 or 60 minutes, prior to western 
blot analysis with an anti-ubiquitin antibody. 
Polyubiquitinated GST-HECTD1CD was 
efficiently deubiquitinated by the AnkOTU 
domain of TRABID, which suggests that 
HECTD1 assembles chains through K29 
and/or K33 linkages, since these are the 
preferred TRABID substrates (Fig 5A) (28). 
Interestingly, remnant short ubiquitin chains of 
size similar to those obtained with UbK29R (Fig 
4E, lane 7) were also detected following 
incubation with TRABID AnkOTU (Fig 5A, 
lanes 3-5 vs. 1). In line with previous data, 















AnkUBD) showed limited activity (28). In order 
to further validate the linkage composition of 
chains assembled by HECTD1, we used 
DUBs of known specificity and which have 
been particularly useful in order to determine 
the linkage composition of ubiquitin chains. 
These included the OTU DUBs Cezanne 
(Cezanne, K11-specific), OTUD3_CD 
(cleaves K6/K11 linkages), the JAMM family 
member AMSH (K63-specific) and its more 
active AMSH* (improved activity towards K63 
chains), and the proteasomal DUBs UCH37 
(cleaves Met-1 and K48-specific linkages) and 
USP14 (cleaves K6/11/48/K63) (31,56,58-62). 
None of these DUBs were able to reduce the 
ubiquitin smear induced by HECTD1 (Fig 5A 
& Supplementary Fig 2A & B). In contrast, 
OTUB1* which has been engineered to have 
increase DUB activity compared to OTUB1, 
showed some activity towards 
autoubiquitinated HECTD1 (Fig 5A, OTUB1* 
lanes 3-5 vs. 2; Supplementary Fig 2C for 
His6-HECTD1CD). To explore the possibility 
that these chains might be of mixed 
composition, through K29 and K48 linkages, 
we incubated autoubiquitinated HECTD1CD 
with both AnkOTU and OTUB1 (Fig 5B). 
However, we observed similar data than for 
the AnkOTU alone treatment (Fig 5B, lanes 5 
and 6 vs. 3). Although the remnant chains that 
remained following AnkOTU treatment can be 
fully processed by USP2, OTUB1* had no 
effect on these chains, which could suggest 
that they might be branched and therefore 
resistant to DUB cleavage (Fig 5B for His6-
HECTD1CD; Supplementary Fig 2D for GST-
HECTD1CD) (55). 
Having established that TRABID NZF 1-3 is 
required for binding HECTD1 in cells and that 
catalytic dead TRABID traps polyubiquitinated 
HECTD1, we then validated this data in the 
context of HECTD1’s newly identified ubiquitin 
ligase activity using a pulldown approach (Fig 
5C-D; Supplementary Fig 3). For this, we used 
His6-HECTDCD instead of GST-HECTD1CD 
since this construct yielded longer 
polyubiquitinated signals which were easier to 
visualise. Importantly, His6-tagged HECTD1CD 
displayed similar ligase activity as the GST-
tagged version, as shown by the marked 
reduction in ubiquitin chain smear in the 
presence of UbK29R or following UbiCREST 
assay with AnkOTU (Fig 5C). 
Polyubiquitinated His6-HECTD1CD, generated 
in vitro, could be efficiently enriched for by 
GST-TRABID NZF 1-3 pulldown but not GST 
alone (Fig 5D, lane 14 vs. 9). As expected, 
there was no clear enrichment when using 
UbK0 in the autoubiquitination reaction, further 
indicating that TRABID NZF 1-3 does not bind 
monoubiquitin (Fig 5D, lane 12) (29,31,32). 
The short ubiquitin species generated by His6-
HECTD1CD using UbK29R, as well as the short 
remnant chains obtained following TRABID 
AnkOTU treatment, were not efficiently 
enriched by TRABID NZF 1-3, suggesting 
these chains might contain linkages with low 
binding affinity for NZF 1-3 (Fig 5D, lanes 13 
& 15). 
To corroborate these findings, we next 
analysed the chains assembled by GST-
HECTD1CD using Ubiquitin-AQUA (Fig 5E-H, 
Supplementary Fig 4, and Supplementary 
Table 2). This revealed that in the presence of 
ubiquitin WT, K48-linked and K29-linked 
ubiquitin chains are the preferred linkages 
used by HECTD1 to assemble polyubiquitin, 
with 44% and 27.7% respectively (Fig 5F). In 
agreement with our UbiCREST data, K29 
linkages almost entirely disappeared following 
incubation with TRABID AnkOTU (Fig 5G). 
We also analysed the remnant ubiquitin 
chains obtained with UbK29R, which revealed 
that in the absence of K29, HECTD1 favours 
K6 to assemble short ubiquitin chains (46.7% 
with UbK29R vs. 5.1% with UbWT) (Fig 5H). 
Interestingly, the HECT ligase UBE3C 
assembles ubiquitin chains through K29 
(47%) and K48 (48%) linkages. However, in 
the context of phosphorylation of ubiquitin at 
Ser 20, UBE3C utilises K48 (79%) and K6 
(6%) (63). This, together, with our data using 
UbK29R, indicates that certain lysine residues 
on ubiquitin are prioritised by HECT ligases to 
assemble chains (64). Linkage prioritisation 
can be regulated by phosphorylation, in the 
case of UBE3C, and it will be interesting to 
determine which post-translational 
modifications on ubiquitin might affect 
HECTD1 specificity, and how. 
HECTD1 and UBE3C assemble distinct 
K29-containing ubiquitin chains 
UBE3C was the first and until now the only 
HECT ligase shown to assemble ubiquitin 
chains through both K29 and K48 linkages 
(45). We next set out to compare whether 
these E3s might both use these linkages to 
assemble chains with the same architecture. 
In vitro autoubiquitination reactions were 
performed with either GST-HECTD1CD or 
GST-UBE3CCD followed by treatment with 
AnkOTU or OTUB1* (Fig 6A, Supplementary 















AnkOTU treatment resulted in a short remnant 
ubiquitin chains for HECTD1 (Fig 6A, lane 3 
vs. 1; Supplementary Fig 5C, lane 3 vs. 1). In 
contrast, the same treatment resolved the 
polyubiquitinated smear produced by UBE3C 
down to the monoubiquitinated species signal 
(Fig 6A, lane 7 vs. 5; Supplementary Fig 5C, 
lane 6 vs. 4). Side-by-side comparison of 
HECTD1CD and UBE3CCD also revealed that 
OTUB1* has a more pronounced effect on 
UBE3C, reducing its ubiquitin smear down to 
the monoubiquitination signal, compared to 
HECTD1CD where a longer smear remained 
following OTUB1* treatment (Fig 6A, lane 4 vs. 
1 for HECTD1CD; lane 8 vs. 5 for UBE3CCD). 
The effect of OTUB1* on polyubiquitinated 
species was more readily observed when 
probing these reactions with a K48-specific 
antibody. In summary, this data suggests that 
HECTD1 and UBE3C both use K29 and K48 
to assemble ubiquitin chains of different 
topologies. This is further emphasised by the 
detection of free ubiquitin chains, in particular 
dimers and trimers, which were readily 
detected following TRABID AnkOTU 
treatment of UBE3C but not HECTD1 (Fig 6A, 
lower panel; Supplementary Fig 5C). 
HECTD1 ligase activity assembles 
ubiquitin chains through branched 
K29/K48 linkages 
In order to determine whether branching was 
required as part of HECTD1 ligase activity to 
assemble K29/K48 chains, we expressed and 
purified an untagged UbK29/K48only mutant and 
used it in autoubiquitination assays (Fig 6B-D; 
Supplementary Fig 5D). We first compared 
GST-HECTD1CD and GST-UBE3CCD in their 
ability to assemble the full extent of ubiquitin 
chains that is seen with UbWT, but in the 
presence of UbK29only, UbK48only or UbK29/48only. 
UBE3C was able to use any of these Ub-only 
mutants to produce a full smear (Fig 6B, lanes 
6-8 vs. 5). In contrast, when using either 
UbK29only or UbK48only, HECTD1 could only 
assemble ubiquitin chains which were shorter 
than those obtained with UbWT, in line with 
data shown in Fig 4D (Fig 6C, lanes 6 & 7 vs. 
5). Strikingly, when using UbK29/K48only, GST-
HECTD1CD was able to recapitulate the full 
activity seen with UbWT (Fig 6C, lane 8 vs. 5). 
To show that this activity for HECTD1 reflects 
branching rather than heterotypic mixed 
chains, we repeated the assay and included a 
reaction which contained both UbK29only and 
UbK48only (Fig 6D). This produced a ubiquitin 
smear which was reminiscent of what we 
obtained with either UbK29only or UbK48only (Fig 
6D, lane 6 vs. 3 & 4). Together, this data 
strongly indicates that the full ligase activity of 
HECTD1 relies on the ability to utilise K29 and 
K48 linkages on the same ubiquitin molecule, 
at least in vitro. In contrast, while UBE3C can 
use these same linkages to assemble chains, 
it does not appear to be reliant on branching. 
This data also could imply that the remnant 
chains observed following treatment with 
AnkOTU or OTUB1*, represent branching 
linkages which cannot be efficiently processed 
by these DUBs. 
Previous work established UBE3C’s 
preference for assembling K29 ubiquitin 
chains within mixed/branched chains (29,65-
67). The viral OTU (vOTU) of the Crimean 
Congo haemorrhagic fever virus (CCHFV), 
which cleaves all but Met-1 and K29-linked 
diubiquitin, has been useful to generate pure 
K29-linked chains for crystallography studies 
(68). We therefore used vOTU to test whether 
it could remove all but K29 linkages and 
provide further insights on the chains 
assembled by HECTD1 and UBE3C 
(29,31,55,68,69). In our assay, high 
concentration of vOTU fully resolved all the 
ubiquitin smears of both E3s, indicating that 
vOTU has the potential to cleave the remnant 
chains we previously observed in a similar 
fashion to USP2 (Supplementary Fig 6A; Fig 
5A). We next used UbK29only chains to titrate the 
concentration of vOTU so that it would not 
cleave K29-linked chains (Supplementary Fig 
6B, lanes 4 and 11) (63). At this lower 
concentration, vOTU showed some weak 
activity towards the chains produced by 
HECTD1 and UBE3C when using UbK29/K48 
(Supplementary Fig 6C). However, high 
molecular weight species could still be 
detected with the K48-specific antibody 
indicating incomplete digestion of this linkage 
by vOTU (Supplementary Fig 6C, upper panel, 
lane 4 vs. 3; lane 10 vs. 9). In summary of this 
data, treatment with vOTU did not provide 
further insights on the assembly of K29/K48 
chains. In line with previous data obtained 
using UbWT, free K48-linked ubiquitin chains 
were also released following AnkOTU 
treatment of polyubiquitinated UBE3CCD, 
when using UbK29/K48 (Fig 6A for UbWT; 
Supplementary Fig 6C, lane 11 for UbK29/K48). 
Having shown that the catalytic domain of 
HECTD1 preferentially assembles ubiquitin 
chains through branching at K29 and K48, we 















context of full-length endogenous HECTD1. 
For this, we used 3xFLAG_FL TRABIDC443S to 
trap endogenous HECTD1HMW species. 
Following immunoprecipitation using an anti-
HECTD1 antibody coupled to Dynabeads®, 
samples were left untreated or were incubated 
with either AnkOTU or OTUB1* for 1 hr at 30 
°C prior to western blot analysis (Fig 7A). The 
HECTD1HMW species that could be enriched 
for in the control reaction (Fig 7A, lane 1), were 
readily processed by AnkOTU but not OTUB1* 
(Fig 7A, lane 2 vs. 3 and 1). We also probed 
these reactions with a monoclonal anti-
ubiquitin antibody which confirmed that the 
ubiquitin chains trapped by the TRABID 
catalytic dead constructs were also sensitive 
to TRABID DUB activity, but not to OTUB1* 
activity (Fig 7A, lane 1 vs. 2 and 3). This is in 
line with TRABID’s preference for binding and 
processing K29, and not K48 linkages. 
To determine whether the observations made 
for GST-HECTD1CD hold true in the context of 
full-length Hectd1, we next assessed the 
ubiquitin ligase activity of HA-tagged full-
length mouse Hectd1. HA-FL mHectd1 was 
expressed and purified from HEK293ET and 
used in in vitro autoubiquitination assays (Fig 
7B). Indeed, we found that HA-full-length 
mHectd1WT but not the catalytic dead mutant 
(C2587G) produced high molecular weight 
ubiquitinated species which could be resolved 
following incubation with TRABID AnkOTU. In 
line with our previous data, UbK29R did not 
support full Hectd1 autoubiquitination activity. 
Together, this data indicates that the HECT 
domain of HECTD1, whether it be in isolation 
or in the context of the full-length protein, 
primarily assembles K29-linked ubiquitin 
chains which are likely branched at K48. 
TRABID stabilises HECTD1 levels 
Some E3 ligases have been shown to pair up 
with DUBs, which enables them to regulate 
each other’s activity and stability (40). 
Therefore, having established that HECTD1 is 
a novel E3 ligase assembling UbK29 and UbK48 
chains, and a substrate of TRABID DUB 
activity, we next evaluated the functional 
relationship of this E3/DUB pair. Individual 
TRABID siRNA were first validated for their 
ability to deplete pEGFP-FL TRABID 
(Supplementary Fig 7), prior to assessing their 
effect on endogenous HECTD1 protein levels 
in HEK293ET cells (Fig 8). All TRABID siRNA 
tested led to a decrease in endogenous 
HECTD1 protein levels (Fig 8A). To further 
validate this, we recapitulated this data in 
HEK293ET and MDCK CRISPR/Cas9 
TRABID KO clones (Fig 8B and C, 
respectively). Importantly, this decrease in 
HECTD1 protein levels could be rescued by 
re-expression of pEGFP-TRABIDWT but not 
pEGFP-Empty vector alone, indicating that 
TRABID directly regulates HECTD1 levels 
(Fig 8D). We extended these observations to 
Trabid KO mice (Trabid-/-) which showed a 
marked reduction in Hectd1 levels in the 
mouse gut epithelium, as well as liver and 
spleen tissues, compared to littermate 
controls (Fig 8E & F). Finally, we used a 
cycloheximide chase assay to study the 
steady state level of HECTD1 upon TRABID 
depletion. This revealed that HECTD1 is 
readily turned over in the absence of TRABID, 
indicating that TRABID association with 
HECTD1 is required for its stability (Fig 8G). 
Discussion 
We previously established that the OTU 
deubiquitinase TRABID preferentially cleaves 
K29 and K33-linked diubiquitin (28). This, 
together with studies defining the biochemical 
properties of TRABID NZF 1, indicates that 
TRABID is highly tuned for the recognition and 
processing of these atypical linkages (29-31). 
Yet, the roles of TRABID DUB activity towards 
K29 and K33 linkages have remained elusive.  
Proteomics studies of full-length TRABID wild 
type as well as of the catalytic dead trapping 
mutant TRABIDC443S have identified a number 
of candidate interactors and potential 
substrates including the E3 ubiquitin ligase 
HECTD1 (33,39). Interestingly, most of the 
proposed mechanisms have been in the 
context of TRABID DUB activity towards K63-
linked ubiquitin chains. Indeed, TRABID can 
clearly also process K63 linkages as shown in 
vitro on hexameric K63-linked ubiquitin 
chains, and also in cells through the 
deubiquitination of APC (28,33). 
We first defined two catalytic dead TRABID 
constructs to identify putative TRABID 
substrates and also to determine the 
contribution of the OTU domain with regard to 
previously reported TRABID interactors. We 
reasoned that the overlap of candidate hits 
between TRABIDC443S and TRABID DOTU 
would implicate NZF interactors and therefore 
should identify likely substrates of TRABID 
DUB activity. In contrast, OTU-specific 
interactors (found in TRABIDC443S but not 
TRABID DOTU) might instead represent 















The kinase/phosphatase STRIPAK complex 
was previously identified in a proteomics study 
of TRABIDWT, and our data now show that this 
interaction is likely mediated by the OTU 
domain of TRABID (39,70). This raises the 
possibility that despite its main role as a 
catalytic domain that mediates docking of 
ubiquitin chains for subsequent cleavage 
through a highly conserved catalytic triad, the 
OTU domain may have additional functions 
which are yet to be identified. As predicted, we 
were able to identify proteins (n = 50) common 
to the interactomes of both TRABIDC443S and 
TRABID DOTU. We hypothesized that this list 
would primarily include candidate TRABID 
substrates likely to be modified with K29- or 
K33-linked chains.  
We validated HECTD1 as a direct substrate of 
TRABID DUB activity and showed that the 
NZF 1 of TRABID is the minimal domain that 
mediates binding to HECTD1. This implied 
that HECTD1 would be modified with either 
K29 and/or K33-linked chains in cells, given 
NZF 1’s affinity for these linkages (29,31). This 
is interesting in light of previous studies 
identifying HECTD1 as a ligase assembling 
K63-linked polyubiquitin chains on the 
Adenomatous Polyposis Coli protein (APC) 
and HSP90, in the context of Wnt signaling 
and cell secretion, respectively (32,33,71). 
HECTD1 has also been proposed to regulate 
K48-linked polyubiquitination on ACF7 in the 
context of EMT (72). Further, K48-linked 
polyubiquitin chains assembled by HECTD1 
have also been implicated in the estrogen-
dependent recruitment of transcriptional 
coactivator/corepressor (73). Therefore, we 
next aimed to reconcile TRABID’s preferred 
DUB activity towards K29 and K33 ubiquitin 
linkages, with the reported specificity of 
HECTD1 ligase activity for assembling K48 
and K63-linked ubiquitin chains. 
In contrast to RING E3 ligases, for which 
linkage specificity is dictated by E2-
conjugating enzymes, the HECT domain plays 
a key role in determining the type of ubiquitin 
chain assembled. Therefore, we next 
determined HECTD1 ubiquitin ligase activity 
using in vitro autoubiquitination assays, 
UbiCREST and Ubiquitin-AQUA. Biochemical 
activity assays showed that, in vitro at least, 
HECTD1 preferentially assembles K29 and 
K48-linked chains. Seminal work by the 
Pickart laboratory on HECT ligase specificity 
established that UBE3C can assemble mixed 
K29/K48 signals, and this has been further 
validated using TRABID NZF 1 to pull down 
ubiquitinated species from cells 
(29,45,65,74,75). Together, this led to the 
proposed model that K29-linked ubiquitin 
canonically exists as heterotypic and/or 
branched signals also containing K48-
linkages. Although AIP4 (ITCH in human) and 
SMURF1 E3 ligases have been proposed to 
assemble K29 linkages on Deltex and Axin, 
respectively, the exact architecture of these 
chains remains unclear. This is also rather 
surprising given that NEDD4 family members 
predominantly generate K63-linked ubiquitin 
chains (76,77). 
Excitingly, our data shows that full HECTD1 
ligase activity requires both K29 and K48 
linkages, indicating the presence of branched 
linkages. Our findings also suggest that while 
HECTD1 and UBE3C can both use K29 and 
K48 linkages, the architecture of the chains 
assembled by either ligase is likely to be 
different, with HECTD1 being more reliant on 
branching compared to UBE3C. It will be 
important to combine recent approaches such 
as Ub middle-down MS/MS, UbProT and Ub-
clipping to further determine the architecture 
of these K29/K48 ubiquitin chains (78-80). For 
instance, middle-down MS/MS has been 
useful to quantify the abundance of branched 
and mixed linkages in cells while Ub-clipping 
has started to unravel ubiquitin chain 
architecture in the context of mitophagy 
(74,80). 
Branched chains were first proposed for K29-
K48 in the context of the Ubiquitin Fusion 
Degradation (UFD) pathway in yeast. Further 
studies revealed that K29-linked polyubiquitin 
chains assembled by Ufd4 are further 
modified with short K48 chains by the E4 
enzyme Ufd2p (81-83). The yeast 
proteasome-associated ligase Hul5 (UBE3C 
in mammals), also acts as an E4 enzyme, 
extending ubiquitin chains on substrates 
bound to the proteasome (84). In the context 
of mammalian cells, UBE3C ligase activity has 
been implicated in the polyubiquitination of 
proteasomal receptor Rpn13 with K29/K48-
linked polyubiquitin, which serves as a 
mechanism to decrease the recruitment of 
ubiquitinated substrates and decongest the 
19S proteasomal lid during proteotoxic stress 
(66). Interestingly, heterotypic K29/K48-linked 
chains have also been found to modify 
cytosolic ERAD clients, with the ER-
embedded E3 ligases TRC8 and UBE3C 















studies, along with other reports on the 
function of branched K11/K48 and K48/K63 
ubiquitin chains regulating mitosis and NFkB 
signaling respectively, have revealed yet 
another layer of complexity within the ubiquitin 
system (21-23). Our data now shows that 
although UBE3C and HECTD1 can assemble 
K29- and K48-linked chains, the exact 
architecture and regulation of these more 
complex ubiquitin chain types will need to be 
deciphered. In particular, it will be important to 
identify substrates of HECTD1 which are 
modified with these chains, and also to 
determine the molecular functions of K29/K48 
branched ubiquitin signals in cells. Together, 
our data identify TRABID-HECTD1 as the first 
DUB-E3 pair regulating K29-linked 
polyubiquitin chains. Interestingly, a recent 
study has shown that the proteasomal subunit 
RPN13 acts as an accessory protein to 
enhance the activity of the DUB UCH37 
towards K48-containing, branched tri-
ubiquitin, and this could provide new ways to 
further explore the assembly/disassembly of 
these more complex ubiquitin chain types 
(85). The ability of some E3s to form branched 
ubiquitin chains, combined with this recent 
report of a debranching DUB activity, further 
exemplifies the versatility of protein 
ubiquitination. 
Transient and genetic loss-of-function/rescue 
assays in mammalian cells showed that 
TRABID-HECTD1 is a functional DUB-E3 pair, 
with TRABID required to maintain HECTD1 
stability. This is also true in vivo were HECTD1 
levels were markedly decreased in tissues 
from Trabid KO mice. The list of validated 
DUB-E3 pairs is rapidly expanding and is 
providing new insights on how the stability or 
activity of these enzymes is regulated (86,87). 
DUBs for instance have been shown to be 
particularly important for maintaining the 
stability of E3s which can autoubiquitinate in 
the absence of a substrate, including BRCA1, 
NEDD4, WWP2, E6AP, Parkin, Hrd1 and 
TRAF6 (88-94). For example, Hrd1 
autoubiquitination has emerged as a key 
requirement for the retrotranslocation of some 
ERAD substrates, while TRAF6 
autoubiquitination is a key event in NFkB 
signaling (93,94).  
Currently, none of the putative cellular 
functions of HECTD1 have been attributed to 
K29-linked polyubiquitination. Future 
interactome and substratome studies will be 
required to uncover the function of HECTD1 
K29/K48 activity along with the molecular 
mechanisms involved. Interestingly, both the 
yeast (Ufd4) and C. elegans (Hecd1) 
ancestors of HECTD1 have been shown to 
function as UFD ligases (95). Our data is in 
line with these studies given that the UFD 
pathway implicates K29/K48 
polyubiquitination. Therefore, it will be 
interesting to further explore the role of 
HECTD1 in the regulation of mutant ubiquitin 
UBB+1 which remains the best characterised 
physiological UFD substrate in human cells 
(96). Overall, our study conveys new insights 
into the regulation of atypical ubiquitin chains 



















COS-7, MDCK, HEK293T and HEK293ET 
cells were grown in DMEM (Dulbecco’s 
modified Eagles Medium) supplemented with 
10% fetal bovine serum (FBS) and 100 U/ml 
penicillin, 100 mg/ml streptomycin at 37°C in 
5% CO2. Cells were regularly checked for the 
presence of Mycoplasma using the 
MycoAlertTM Mycoplasma Detection Kit 
(Lonza Group AG, Switzerland). 
Transient siRNA knock down 
TRABID siRNA used included ON 
TARGETplus SIRNA SMARTpool and 
individual siRNA #6, #7, #8 and #9 from 
DharmaconTM (GE Healthcare, Dharmacon, 
Inc., Lafayette, CO, USA), individual siRNA for 
#1 and #2 (32),  #1 and #5 (97). A non-
targeting siRNA as well as ON TARGETplus 
SIRNA pool or an individual sequence for 
human HECTD1 were used as controls for 
HECTD1 levels. Oligos were synthesized by 
Eurofins Scientific (Luxembourg).  
Trabid (Zranb1) knockout mice 
Animal care and procedures were performed 
in accordance with the standards set by the 
United Kingdom Home Office. Two ES cells 
clones were purchased from EUCOMM and 
injected into Blastocyst (TYR) and then 
injected into C57BL/6N (substrain JM8A1.N3) 
at the MRC Laboratory of Molecular Biology, 
Cambridge, in ES cells. To excise exon 3 and 
the neomycin cassette ZranG11 mice were 
crossed to P214 67deletor mice (98).  To 
confirm the excision standard PCR was used 
with primers ZrnaGNeoF1: 
CTCATGCTGGAGTTCTTCGC; H5R2: 
CATACAAGCAAGCAAAAGATTCA. 
Genotyping was done by a standard PCR with 
primers H5F: GCTGTTCCAGTGGTCCTGAG; 
EX3R: TGGCTGCTAAGTCACCTTCC; LAR3: 
CACAACGGGTTC CTTCTGTTAGTCC. 
CRISPR/Cas9 genome editing in cells 
Trabid KO cells were generated as described 
(99). Briefly, the design tool CRISPOR 
(crispor.tefor.net) was used to design single-
stranded oligomers for sgRNA targeting 
vectors. RNA-encoding plasmid derivatives of 
pSpCas9(BB)2A-GFP (PX458) were 
generated by hybridizing single-stranded 
oligomers with their complementary strands in 
2 mM Tris-HCl (pH 7.4), 10 mM NaCl, 200 mM 
EDTA at 95˚C for 5 min, and by subsequently 
ligating the double-stranded oligomers into a 
BbsI restriction site of PX458. HEK293T or 
MDCK cells were sorted 48h post-transfection 
at a density of 1 cell/well in a 96-well plate and 
grown for 14–20 days to isolate individual 
clones.  For genotyping, 2–5x104 cells were 
homogenized in 15 µl MicroLYSIS-Plus 
(Microzone, Haywards Heath, UK) and 
thermocycled as specified by the 
manufacturers. 2 µl of supernatant was used 
for PCR amplification, and the resulting PCR 
products were purified using the QIAquick 
purification kit (Qiagen, Hilden, Germany) and 
sequenced. Sequence chromatograms were 
analysed using TIDE webtool 
(https://tide.deskgen.com/) and checked using 
MacVector software (MacVector Inc., Cary 
NC, USA). Human gRNA and primers were 
used for HEK293T and dog gRNA and primers 
were used for MDCK cells: 
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GTACCCAGTGCTTATCCC); dog Zranb1 




GTACCCAGTGCTTATCCC); dog Zranb1 






pGEX-6p1 (GE Healthcare Life Sciences) 
encoding UBE3C, UBE2D1 (UBCH5A), 
UBE2D2 (UBCH5B) and UBE2D3 (UBCH5C) 















Laboratory of Molecular Biology, Cambridge, 
UK). Human HECTD1 (AA2129-end) was 
amplified using cDNA from Normal Human 
Bronchio Epithelial cell line (NHBE) and 
cloned using BamH1/Xho1 into pGEX-6p1 
(GST-HECTD1) or into pETM-11 using 
NCO1/XHo1 (His6-HECTD1) (46). Full-length 
HA-mouse-Hectd1 was a kind gift from Irene 
Zohn (71). Mouse full-length Hectd1 was 
subcloned into pEGFP-C1 (Clontech) and 
pCMV-3Tag1-3xFLAG (Agilent). 
Recombinant proteins 
Expression and purification of TRABID 
Catalytic Domain (CD) (AnkOTU) has been 
described previously (28). His6-UBE1 (E-304), 
and DUBs including His6-Otubain-1 (OTUB1; 
E-522B), His6-OTUD7B/Cezanne (E-562), 
OTUD3_CD (E-574), AMSH/STABP (E-
548B), USP2_CD (E-504), UCH37 (E-327), 
and USP14 (E-544) were purchased from 
R&D Systems, Inc (Minneapolis, MN, USA). 
Bovine ubiquitin was purchased from Sigma-
Aldrich-Aldrich (St Louis, MS, USA; U6253). 
vOTU was gene synthesized (204AA, Mw = 
23,241 g/mol) (56). AMSH* and OTUB1* have 
shown improved activity over AMSH and 
OTUB1, respectively. pOPINB-AMSH* was a 
gift from David Komander (Addgene plasmid # 
66712 ; http://n2t.net/addgene:66712 ; 
RRID:Addgene_66712), pOPINB-OTUB1* 
was a gift from David Komander (Addgene 
plasmid # 65441 ; 
http://n2t.net/addgene:65441 ; 
RRID:Addgene_65441) (31).  
Ubiquitin mutants including UbK0, UbMet, UbK/R 
and UbKonly, and the recombinant Human 
UbcH (E2) enzyme set Protein (K-980B) were 
purchased from R&D Systems. GST-HECTD1 
and GST-UBE3C, GST-tagged UBE2D1, 2 
and 3 were expressed in Escherichia coli BL21 
DE3 (RIL) (Agilent Technologies, Inc. Santa 
Clara, California, USA) and purified by affinity 
chromatography followed by gel filtration 
(GST-HECTs). GST-UBE2Ds were eluted 
with reduced glutathione prior to desalting with 
an HiTrap Desalting column. To remove the 
GST tag, GST-UBE2Ds were incubated 
overnight with PreScission protease (GE 
Healthcare, Chicago, IL, USA) (28,46). 
Fractions were concentrated, quantified using 
a NanoDrop 2000c and 1 mg/ml stocks were 
aliquoted, flash-frozen in liquid nitrogen and 
stored at -80°C. UbK29/K48only was expressed in 
BL21 DE3 (RIL), purified by perchloric acid 
extraction followed by ion exchange and gel 
filtration using established protocols and the 
mass was check by Liquid Chromatography 
Mass Spectrometry using a 6545 LC/QTOF 
(Agilent Technologies) (100).  
Antibodies 
Primary antibodies used were: anti-b-actin 
(Abcam Cambridge, UK, 8227 or Sigma-
Aldrich, A5441), anti-b-Catenin (Cell Signal, 
Danvers, MA, USA, #9562), anti-E-Cadherin 
(Cell Signaling, #24E10), anti-HA High Affinity 
(Roche, Germany, 3F10), anti-FLAG® M2 
mouse monoclonal (Sigma-Aldrich, #A2220), 
anti-GST goat polyclonal (GE Healthcare, 
#27-4577-01), anti-GFP monoclonal antibody 
(GF28R) (ThermoFisher Scientific, MA5-
15256), anti-GSK3b (Cell Signaling, #27C10), 
anti-HECTD1 (Abcam, Ab101992), anti-
HERC2 (Abcam, Ab85832), anti-UBE3C 
(Abcam, Ab180113), anti-TRIP12 (Abcam, 
Ab86220), anti-NEDD4 (Abcam, Ab14592), 
anti-polyubiquitin (linkage-specific K48 
antibody [1001C]; Abcam, Ab190061), anti-
ubiquitin rabbit polyclonal (MilliporeSigma-
Aldrich, Burlington, MA, USA; #07-375), anti-
ubiquitin mouse monoclonal (Enzo 
Lifesciences; P4D1; BML-PW0930), and anti-
His6-HRP (Sigma-Aldrich, #A7058). 
Secondary antibodies used for ECL detection 
goat anti-rabbit IgG-HRP (sc-2054), Donkey 
anti-goat IgG-HRP (sc-2020) and goat anti-
mouse IgG-HRP (sc-2005), goat anti-rat IgG-
HRP (sc-2032) (All from Santa Cruz 
Biotechnology, Inc, Dallas, TX, USA). For 
near-infrared western blot detection, IRDye® 
680RD donkey anti-goat secondary (P/N 925-
68074), IRDye® 800CW goat anti-mouse 
secondary (P/N 925-32210), IRDye® 680RD 
goat anti-mouse secondary (P/N 925-68070) 
and IRDye® 680RD goat anti-rabbit secondary 
(P/N 925-68071) were used (All from LI-COR 
Biosciences, Lincoln, Nebraska, USA). 
Transfection 
Transfections of plasmid DNA in HEK293T 
cells were performed using either 
lipofectamine 2000 or polyethylenimine (PEI, 
linear, MW 25,000, Polysciences, Warrington, 
PA, USA). Typically, for 1 µg of plasmid DNA, 
3 µl of a 1 mg/ml PEI solution was used. For 
siRNA, HEK293ET cells were transfected with 
lipofectamine 2000 as indicated by 
ThermoFisher Scientific (Waltham, MA, USA). 
Immunoblotting 
Cells were lysed in Triton Lysis Buffer (150 
mM NaCl, 25 mM Tris, 1% Triton X-100 















protease inhibitor cocktail) or RIPA (150 mM 
NaCl, 50 mM Tris pH 8, 1% NP40, 0.5% 
NaDoc, 0.1% SDS, supplemented with 
cOmpleteTM EDTA-free protease inhibitor 
cocktail) as indicated. Cell lysates were 
denatured in 4X LDS/100 mM DTT and 
resolved on 4-12% Bris-Tris or 3-8% Tris 
Acetate SDS-PAGE gels under reducing 
conditions and transferred to a polyvinylidene 
difluoride membrane (PVDF, 0.45 µM, 
ThermoFisher Scientific) or Millipore 
Immobilon® FL for near-infrared fluorescence 
detection by LI-COR® Clx. Membranes were 
blocked in 5% (w/v) non-fat dried skimmed 
milk powder in PBST (PBS, 0.1% Tween-20) 
for 1 hour at room temperature (RT). 
Membranes were then probed with the 
appropriate primary antibodies in blocking 
buffer overnight at 4°C. Detection was 
performed by incubating membranes with the 
appropriate horseradish peroxidase (HRP)-
conjugated or IRDye secondary antibodies in 
blocking buffer at RT for 1 hour. Enhanced 
Chemiluminescence (ECL) (ThermoFisher 
Scientific) was used for anti-ubiquitin western 
blots and images were acquired on a FUSION-
SL imager (Vilber Lourmat, France). 
Alternatively, anti-GST blots were visualized 
on a LI-COR® Clx (46).  
Western Blot for mouse tissue analysis 
For mice tissues analyses, small intestines 
were removed immediately after cervical 
dislocation, opened longitudinally and washed 
with cold PBS. Remaining mucosa was 
removed with Kimcare tissue (Kimberly-Clark, 
Irving TX, USA). The epithelia were separated 
from their underlying mucosa by scraping the 
small intestines with a razor blade, flash-
frozen in liquid nitrogen, and stored at -80°C 
for less than 24 months. Protein extracts were 
prepared from mouse small intestine 
epithelium by adding a small fragment of flash-
frozen mouse gut directly into NuPage LDS 
loading buffer containing 5% b-
mercaptoethanol, and mechanically 
homogenising on ice. Extracts were sonicated 
twice for 10 sec on ice before western-blot 
analysis.  
Immunoprecipitation 
Cells were transfected with 500 ng of each 
plasmid per well of a 6-well plate using 
Lipofectamine 2000 (ThermoFisher Scientific) 
in Opti-MEMTM using a 3:1 Lipofectamine:DNA 
ratio for 24 hrs-48hrs. Each well was lysed in 
400 µl of Triton Lysis Buffer for 15 minutes on 
ice. Lysates were cleared by centrifugation at 
13,000 rpm for 15 minutes at 4°C. FLAG-
tagged proteins were captured using FLAG® 
M2 magnetic beads (Sigma-Aldrich) while 
GFP-tagged proteins were captured with 
GFP-Trap®_MA (ChromoTek GmbH, 
Germany) for 1 hr at RT, as per the 
manufacturer’s protocol. Beads were washed 
four times in Triton Lysis Buffer and denatured 
at 95°C for 5 min in 2X LDS/100 mM DTT. 
Samples were then resolved on 4-12% Bis-
Tris or 3-8% Tris Acetate SDS PAGE gels and 
analysed by western blotting. For 
immunoprecipitation of endogenous HECT 
ligases, 2 µg of Dynabeads® magnetic beads 
protein G (ThermoFisher Scientific, #10003D) 
were wash 3x times in Triton Lysis Buffer prior 
to coupling with 4 µg of anti-HECT antibody. 
Following 1 hr incubation at RT on a rotating 
wheel, Anti-HECT-coupled magnetic beads 
were washed 3x times in Triton Lysis Buffer 
and added to 390 µl of lysis buffer, while 10 µl 
of each lysed sample was kept as input 
controls. Following 1 hr incubation at RT, 
beads were washed 4 times in Triton Lysis 
Buffer and both the input and IP samples were 
denatured at 95°C for 5 min in 2X LDS/100 
mM DTT. Samples were then resolved on 4-
12% SDS PAGE gels and analysed by 
western blotting. Typically, the input ran on a 
gel represented 2.5% of the initial 400µl 
lysate, and we ran half of the final denatured 
IP samples. HA-tagged full-length HECTD1 
was expressed and purified from HEK293ET 
using PierceTM anti-HA Magnetic Beads 
(ThermoFisher Scientific, #88836) using 
standard procedures (28). 
For ubiquitin trapping IP (Supplementary Fig 1 
B), 3xFLAG TRABID constructs (500 ng/well 
of a 6-well plate) were transfected with HA-
ubiquitin (500 ng/well of a 6-well plate) with 
lipofectamine 2000 in HEK293ET cells. 
Twenty-four hours post transfection, cells 
were harvested, lysed in Triton Lysis Buffer, 
and FLAG-tagged proteins were captured 
using FLAG® M2 magnetic beads (Sigma-
Aldrich). Input and IP samples were analysed 
by western blotting using anti-FLAG and anti-
HA antibodies, respectively. 
To further validate TRABID-HECTD1 
interaction, 250 ng of pEGFP-tagged and 
3xFLAG-tagged TRABID and Hectd11 
plasmids were co-expressed for 24 hrs in 6-
well plates, in antibiotic-free DMEM/FBS. PEI 
was used for transfection. Twenty-four hours 















lysed in Triton Lysis Buffer and 
immunoprecipitation assays were carried out 
as mentioned above. 
Cycloheximide (CHX) chase. 
HEK293ET cells were transiently transfected 
with 20 pmol of SMARTpool siRNA for 72 hrs 
prior to incubation with 10 µg/ml of 
cycloheximide. Samples were collected at the 
indicated timepoints and lysed in RIPA 
(supplemented with 1X EDTA-free protease 
inhibitor tablets). 
In vitro autoubiquitination assay 
Autoubiquitination assays were carried out in 
10 µl reactions containing 100 ng of His6-E1, 
500 ng of indicated E2, 2.5 µg of His or GST-
tagged HECT E3 ubiquitin ligase, 2.5 µg of 
ubiquitin, in 1x Ubiquitination assay buffer (25 
mM Tris, pH 7.4, 20 mM NaCl, 10 mM MgCl2, 
1 mM DTT, 1 mM ATP) (46). Reactions were 
carried out at 30°C for 3 hours and stopped by 
addition of 2X LDS Sample Buffer/100 mM 
DTT. Samples were then analysed by 
immunoblotting. 
Ubiquitin Chain Restriction Analysis 
(UbiCREST) 
UbiCREST was carried out as described 
(55,56). Briefly, samples obtained from in vitro 
autoubiquitination were treated for 20 minutes 
at RT with 2 mU of Apyrase (Sigma-Aldrich, 
A2230) prior to incubation 1X DUB buffer 
(50mM NaCl, 50mM Tris, pH 7.4 and 50 mM 
DTT) with either TRABID AnkOTU (1 or 2.5 
µM, as indicated), OTUB1/OTUB1* (2 µM), 
Cezanne (1 µM), AMSH/AMSH* (2 µM), 
OTUD3_CD (2 µM), USP2_CD (1 µM), yUbp6 
(1 µM), vOTU (3 µM), UCH37 (200 nM), 
USP14 (1 µM). Reactions were arrested by 
addition of 2X LDS/100 mM prior to western 
blot analysis using the indicated antibodies. 
UbiCREST assay of trapped endogenous 
polyubiquitinated HECTD1 (HECTD1HMW) 
Five micrograms of 3xFLAG-TRABID FL 
TRABIDC443S were transiently transfected in 
one 10 cm dish of HEK293T cells using PEI. 
Twenty-four hours post transfection, cells 
were rinsed with PBS and lysed Triton Lysis 
Buffer (supplemented with EDTA-free 1X 
protease inhibitor). Twenty microliters of 
Dynabeads® protein G magnetic beads slurry 
was rinsed with lysis buffer and incubated for 
2 hrs at RT with four micrograms of HECTD1 
antibody, as per manufacturer’s 
recommendations. Following coupling, beads 
were rinsed 3 times in lysis buffer and 
incubated with the lysate from 3xFLAG-
TRABID FL TRABIDC443S-expressing 
HEK293T cells. Two hours after incubation, 
beads were captured using a magnet and 
washed 4 times in lysis buffer and twice in 1X 
DUB buffer. Beads were finally incubated in a 
10 µl reaction and incubated with AnkOTU 
(1µM) or OTUB1* (2µM). A control reaction 
without DUB treatment was also carried out. 
Samples were incubated for 1 hr at 30°C upon 
which reactions were arrested by addition of 
2X LDS/100mM DTT, resolved on a 3-8% 
PAGE gel and analysed by western blotting. 
GST pulldown 
Autoubiquitination assays obtained with UbK0, 
UbWT, or UbK29R and subjected to UbiCREST, 
were used in GST pulldown experiments. GST 
pulldown was carried out as described 
previously (26). Briefly 20 µg of GST or GST-
TRABID NZF 1-3 (AA1-200) was incubated 
with 20 µl of Glutathione Magnetic Agarose 
Beads (ThermoFisher Scientific) for 1 hr at RT 
in 500 µl of Pulldown Buffer (PDB; 150 mM 
NaCl, 25 mM Tris pH 7.4, 5 mM DTT and 0.1% 
NP-40), and then washed 4 times with PDB. 
Washed beads were incubated with each of 
the indicated in vitro autoubiquitination assays 
in 500 µl of PDB supplemented with BSA (0.5 
mg/ml) overnight at 4°C. Beads were washed 
5 times in PDB and following the final wash 
beads were mixed with 2X LDS/100 mM DTT. 
Samples were analysed on a 4-12% SDS 
PAGE followed by western blotting using anti-
ubiquitin mouse monoclonal (Enzo 
Lifesciences; P4D1 anti-ubiquitin antibody) or 
by silver staining (ProteoSilverTM, Sigma-
Aldrich). 
GST pulldown was also used to further 
validate the interaction between TRABID and 
HECTD1. Here 20 µg of either GST, GST-
TRABID NZF 1-3 or GST-TRABID NZF 1-
3TY>LV were coupled to Glutathione Magnetic 
Agarose Beads for 1hr at RT followed by 
washes with PDB. One 10 cm dish of 
HEK293T cells was lysed in Triton Lysis Buffer 
supplemented with EDTA-free protease 
inhibitor tablet (1X) for 20 minutes on ice 
followed by centrifugation at 15,000 rpm for 15 
min in a refrigerated centrifuge. The cleared 
lysate was split into three equal parts and 
incubated with the GST-coupled beads for 2 
hrs at RT in PDB supplemented with BSA (0.5 
mg/ml). Beads were washed 5 times in PDB 
and finally mixed with 2X LDS/100 mM DTT 















Interactome studies  
Mass Spectrometry. Twenty 175 cm2 flasks 
of sub-confluent HEK293ET cells were 
transfected with either pCMV-3xFLAG_EV, 
pCMV-3xFLAG_Full-length human 
TRABIDC443S or pCMV-3xFLAG_TRABID 1-
339/(=DOTU). Cells were lysed in Triton Lysis 
Buffer and cleared by centrifugation for 20 min 
at 13,000 rpm at 4°C. Supernatant were 
incubated for 1 hr at room temperature with 
FLAG® M2 magnetic beads (Sigma-Aldrich) 
followed by four washes with 1 ml of lysis 
buffer. Beads were finally resuspended in 2X 
LDS sample buffer/100 mM DTT and 
incubated at 95°C for 5 min. Denatured 
samples were then resolved on a 4-12% Bis-
Tris SDS polyacrylamide gel and the gel was 
stained with Imperial Protein Stain 
(ThermoFisher Scientific). IP experiments 
were n = 1 for each of the three plasmids. 
Polyacrylamide gel slices (1-2 mm) containing 
the purified proteins were prepared for mass 
spectrometric analysis by manual in situ 
enzymatic digestion. Briefly, the excised 
protein gel pieces were placed in a well of a 
96-well microtitre plate and destained with 
50% v/v acetonitrile and 50 mM ammonium 
bicarbonate, reduced with 10 mM DTT, and 
alkylated with 55 mM iodoacetamide. After 
alkylation, proteins were digested with 6 ng/µL 
Trypsin (Promega, UK) overnight at 37 °C. 
The resulting peptides were extracted in 2% 
v/v formic acid, 2% v/v acetonitrile. The digest 
was analysed by nano-scale capillary LC-
MS/MS using a Ultimate U3000 HPLC 
(ThermoScientific Dionex, San Jose, USA) to 
deliver a flow of approximately 300 nL/min. A 
C18 Acclaim PepMap100 5 µm, 100 µm x 20 
mm nanoViper (ThermoScientific Dionex, San 
Jose, USA), trapped the peptides prior to 
separation on a C18 Acclaim PepMap100 3 
µm, 75 µm x 250 mm nanoViper 
(ThermoScientific Dionex, San Jose, USA). 
Peptides were eluted with a gradient of 
acetonitrile. The analytical column outlet was 
directly interfaced via a nano-flow electrospray 
ionisation source, with a hybrid dual pressure 
linear ion trap mass spectrometer (Orbitrap 
Velos, ThermoScientific, San Jose, USA). 
Data dependent analysis was carried out, 
using a resolution of 30,000 for the full MS 
spectrum, followed by ten MS/MS spectra in 
the linear ion trap. MS spectra were collected 
over a m/z range of 300–2000.  MS/MS scans 
were collected using a threshold energy of 35 
for collision induced dissociation. LC-MS/MS 
data were then searched against a protein 
database (UniProt KB, 2019. Swiss-Prot, 
563,552 entries. TrEMBL, 195,104,019 
entries) using the Mascot search engine 
programme, version 2.4 (Matrix Science, UK) 
(101). Database search parameters were set 
with a precursor tolerance of 5 ppm and a 
fragment ion mass tolerance of 0.8 Da. 
Trypsin specificity was set as C-terminal side 
of lysine and arginine amino acid unless a 
proline residue was present on the carboxyl 
side of the cleavage site. Two missed enzyme 
cleavages were allowed and variable 
modifications for oxidized methionine, 
carbamidomethyl cysteine, pyroglutamic acid, 
phosphorylated serine, threonine and 
tyrosine, along with GlyGly and LeuArgGlyGly 
lysine were included. MS/MS data were 
validated using the Scaffold programme 
(Proteome Software Inc., USA) (102) with a 
0.2% FDR calculated with peptide 
probabilities estimated using ProteinProphet.  
All data were additionally interrogated 
manually. 
Data interrogation. From an initial list of 
2,225 proteins (95% protein threshold, 
minimum of 2 unique peptides in any of the 
three conditions), proteins with 1 or more 
unique peptide in the control IP (3xFLAG-
Empty vector) were removed, resulting in a 
working list of 208 proteins. We also included 
in this list 7 proteins which did not fulfil the 
criterion above, but which were nevertheless 
included on the basis that these were either 
part of the STRIPAK complex (STRN, STRN3, 
Zinedin) or E3 ligases (HERC2, MYCBP2, 
UBR4, UBE3A) (Supplementary Table 1). 
From this list of 215 proteins, we then applied 
criteria of zero unique peptide in the TRABID 
DOTU condition and at least 2 unique peptides 
in the FL TRABIDC443S condition, which yielded 
103 OTU-specific candidates. We applied 
criteria of zero unique peptide in the TRABID 
FLC443S condition and at least 2 unique 
peptides in the TRABID DOTU condition, 
which produced 23 TRABID DOTU-specific 
candidates. Finally, we applied criteria of zero 
unique peptide in the empty vector control IP 
and 2 at least 2 unique peptides in TRABID 
FLC443S and/or TRABID DOTU, which resulted 
in 50 candidate substrates. 
Ubiquitin-Absolute QUAntification 
(ubiquitin-AQUA) analysis 
GST-HECTD1 was used in autoubiquitination 















HECTD1 using either ubiquitin WT (UbWT) or 
UbK29R (R&D Systems). Reactions were 
stopped after 3 hrs with addition of 2X 
LDS/100 mM DTT. In order to analyse the 
ubiquitin chains left on GST-HECTD1 
following cleavage of K29-linked ubiquitin 
chains, autoubiquitination reaction with GST-
HECTD1 was arrested after 3 hrs using 2 mU 
of Apyrase for 20 minutes at RT prior to 
incubation with 2.5 µM of TRABID AnkOTU. 
Five microliters of each reaction were resolved 
on a 4-12% Bis-Tris PAGE gel and detected 
by western blot using an anti-ubiquitin 
antibody. The remaining 30 µl were run on a 
4-12% Bis-Tris PAGE gel stained with 
Coomassie stain. Gel slices, two areas per 
experimental condition (A/B/C1, A/B/C2), 
corresponding to polyubiquitinated GST-
HECTD1 were cut out of the gel 
(Supplementary Figure 4B), subjected to in-
solution trypsin digestion and quantitatively 
analysed by LC-MS/MS as reported (57,103-
105). A heavy labelled peptide standard mix 
representing all seven Lys-linkages (K6, K11, 
K27, K29, K33, K38 and K63; Thermo Fisher 
Scientific/Sigma-Aldrich, Supplementary 
Table 2) was prepared and spiked into the 
digested peptide samples at a final 
concentration of 10 fmol/µl) prior to LC-MS/MS 
analysis in data-dependent analysis (DDA) 
mode.  For MS data analysis and 
quantification, a targeted proteomics protocol 
adapted to MS/MS acquisition was used 
based on the Skyline workflow and adapted for 
measuring the absolute quantity of Ub-
linkages (Ub-AQUA) (106). To this end, raw 
MS files were processed through 
ProteoWizard to generate mgf files that were 
searched using the Mascot search engine as 
described above. Mascot data /files were used 
and imported into the Skyline software 
(version 64-bit, 19.1.0.193) to generate a 
Ubiquitin-specific peptide library including all 
the Ub linkages represented as Lys-GlyGly 
modifications as well as heavy labelled 
standards. Raw MS files were then imported 
into the Skyline software and matched against 
the Ub-peptide library. Single ion 
chromatograms were extracted automatically, 
representing the m/z of Ub derived tryptic 
peptides carrying Lys-GlyGly modifications. 
To calculate the Ub-linkage abundance, the 
heavy (standard) versus light (experiment) 
abundance ratios determined based on the 
MS1 peak intensities (Supplementary Figures 
4A and Supplementary Table 2).  
Microscopy 
COS-7 cells were transfected with the 
indicated pEGFP-tagged TRABID plasmids 
(Supplementary Fig 1C) fixed and visualised 
as previously described (28). For 
Supplementary Fig 7, HEK293ET cells were 
transfected with pEGFP-full-length TRABIDWT 
(200 ng/ well of a 24-well plate) together with 
20 pmol of the indicated siRNA. Forty-eight 
hours following transfection, cells were fixed 
with 4% paraformaldehyde and imaged on an 
EVOS Cell Imaging System (ThermoFisher 
Scientific). 
Data availability 
The mass spectrometry proteomics data have 
been deposited to the ProteomeXchange 
Consortium via the PRIDE partner repository 
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Figure 1. TRABID catalytic dead interactomes reveals OTU-dependent and independent 
interactors. 
A) Domain organisation of the catalytic dead TRABID constructs used in this proteomics study, 
TRABID DOTU and Full-Length (FL) TRABIDC443S. Key features include the three Npl14-zinc finger 
(NZF) Ubiquitin binding domains (25,32), the AnkUBD (28) and the OTU catalytic domain (24). B) 
pCMV-3xFLAG_EV, TRABID DOTU or FL TRABIDC443S were transiently expressed in HEK293ET. 
Following immunoprecipitation (IP) with FLAG® M2 magnetic beads, samples were subjected to 
SDS-PAGE and gel slices were cut and analysed on an Orbitrap velos (IP experiments were n = 1 
for each of the three plasmids). A selection of candidates TRABID interactors is shown, with the 
number of unique peptides. Note that STRIPAK components were previously reported, and our data 
now identifies the OTU as the domain on TRABID mediating interaction with components of this 
complex (39). From a list of 2,225 proteins, only those with zero unique peptide in the empty vector 
condition were shortlisted for further analysis (n= 208). We also included in this list 7 proteins which 
did not meet this criterion, on the basis that these were part of the STRIPAK complex (STRN, 
STRN3, Zinedin), or that they were E3 ligases (HERC2, MYCBP2, UBR4, UBE3A), bringing the 
working list to n= 215 (Supplementary Table 1). We applied a cut off of at least 2 unique peptides to 
generate the OTU-specific list (n= 103), the TRABID DOTU-specific list (n= 23) and a candidate 
substrate list common to TRABID DOTU or FL TRABIDC443S (n= 50). C) Venn diagram showing 
selected candidate interactors for each and also for both catalytic dead TRABID constructs. Given 
the role of the NZF domains in ubiquitin binding, the list common to both constructs likely represents 
substrates of TRABID DUB activity. D) Validation of HECTD1 as TRABID interactor. pCMV-
3xFLAG_EV, TRABID DOTU or FL TRABID DOTUTY>LV were transiently expressed in HEK293ET 
cells. Twenty-four hours following transfection, cell lysates were incubated with Dynabeads® 
magnetic beads coupled with antibodies for the indicated HECT ligases. IP samples and input were 
analysed by western blot using the indicated antibodies. NEDD4 was not found in our interactome 
and was used as negative control. TRIP12 could barely be detected, which is not surprising given 
its reported nuclear localisation. Note that the membrane had to be overexposed in order to detect 
3xFLAG TRABID DOTU in the HERC2 IP E) Immunoprecipitation assays showing the interaction 
between ectopically expressed TRABID and HECTD1. pCMV-3xFLAG_Ev, FL TRABIDWT or FL 
TRABIDC443S were transiently expressed together with either pEGFP-Ev, pEGFP-FL mouse 
Hectd1WT or pEGFP-FL mouse Hectd1C2587G as indicated. FLAGÒ M2 beads were used to 
immunoprecipitate FLAG-tagged plasmids. Note the enrichment of higher molecular weight species 
of Hectd1 (Hectd1HMW) in the condition where catalytic dead TRABID has been co-expressed (IP 
FLAG/WB GFP, lane 8 vs. 5). Hectd1HMW are markedly reduced in the catalytic dead-Hectd1 
condition (IP FLAG/WB Ubiquitin, lane 9 vs. 8). TRABID catalytic dead traps high molecular weight 
ubiquitin species (IP FLAG/WB Ubiquitin; Lane 8 vs. 5), unless catalytic dead Hectd1 is co-
expressed (IP FLAG/WB Ubiquitin, lane 8 vs. 9). This suggests that TRABID DUB activity regulates 
ubiquitin chains on Hectd1. Reciprocal IPs with FLAG-tagged FL mHectd1 and GFP-tagged FL 
















Figure 2. Mapping of TRABID-HECTD1 interaction. 
A) Domain organisation of TRABID constructs used to map the interaction with HECTD1. The point 
mutation C443S abrogates TRABID DUB activity while TY>LV mutations in each of the three NZF 
abrogates their ability to bind ubiquitin. B) Immunoprecipitation assay using the indicated 3xFLAG-
TRABID deletion constructs, showing that TRABID 1-200 (NZF 1-3) is key for its interaction with 
endogenous HECTD1. Constructs were transiently expressed for 24 hrs in HEK293ET cells prior to 
immunoprecipitation with FLAGÒ M2 beads, followed by western blot analysis. C) 
Immunoprecipitation assays performed as in B), using either catalytic dead-constructs (Lanes 2, 4, 
6), their cognate triple NZF mutant (TY>LV) (Lanes 3, 5, 7) or FL TRABIDWT (Lane 8). Note that 
HECTD1 higher molecular weight species (HECTD1HMW) could be detected in all conditions apart 
from 3xFLAG-Ev and 3xFLAG-TRABIDWT IPs. High exposure (HE) of the membrane following ECL 
detection was necessary to show these HMW species. Note that residues mutated in TRABID NZFs 
(TY>LV) affect their ability to bind ubiquitin but not their fold, and all three NZFs were mutated in 
these constructs (25,32). D) Domain organisation of constructs containing either individual or 
multiple NZFs as indicated. The NZF triple mutant is also depicted. 3xFLAG-TRABID NZF (E) or 
pEGFP-TRABID NZF (F) constructs were used to identify the minimal region that mediated 
interaction with endogenous HECTD1. Constructs were transiently transfected as in B and C. 
Depending on whether one or two NZF were included, the construct expressed differently, hence 
why we also tried GFP-tagged constructs which improved the expression of individual NZFs (F). 
High exposure of blots is provided to better visualise the different level of expression of these 
constructs and also to show that NZF 1 is the minimal domain mediating HECTD1 interaction (F, 
lane 3). Note the clear reduction in signal in the TRABID NZF 1-3TY>LV (E, lane 3 vs. 2; F, lane 2 vs. 

















Figure 3. TRABID NZFs are required for trapping ubiquitin and endogenous HECTD1. 
A) GST pulldown assays were carried using 20 µg of either GST, GST-TRABID NZF 1-3 or GST-
TRABID NZF 1-3TY>LV. Loss of ubiquitin binding through TY>LV mutations abrogates binding with 
endogenous ubiquitin and endogenous HECTD1. B) Immunoprecipitation assays showing that 
endogenous HECTD1, but not HERC2, binds TRABID. This data also shows that HECTD1 and 
HERC2 do not interact, at least in this assay. 4 µg of either HECTD1 or HERC2 antibody were 
coupled to Dynabeads® magnetic beads and incubated with lysates of HEK293T cells expressing 
either 3xFLAG-Ev or 3xFLAG-FL TRABIDC443S. Following 4 washes with lysate buffer, 2X LDS/100 
mM DTT was added to the beads, and samples were heated for 5 min at 95°C followed by western 
















Figure 4. HECTD1 catalytic HECT domain autoubiquitinates. 
A) In vitro autoubiquitination assay performed as previously described (46). GST-HECTD1CD 
(Catalytic domain of human HECTD1, boundaries AA2129-End) was incubated in the presence of 
E1 (UBE1), ubiquitin, and the indicated E2 conjugating enzymes. Reactions without ATP, ubiquitin 
or E2 were included as controls. Reactions were stopped after 3 hrs at 30°C by the addition of 2X 
SDS/100mM DTT and analysed by western blotting using anti-ubiquitin (Top panel) and anti-GST 
(Lower panel) antibodies. The ubiquitin smear observed reflects the autoubiquitination of GST-
HECTD1CD and was used as readout for ubiquitin ligase activity. B) Autoubiquitination assays were 
carried out as in A, using UBE2D1 and either GST-HECTD1WT, or the indicated catalytic dead 
constructs, GST-HECTD1C2579G or GST-HECTD1C2579A. C) In vitro assay showing His6-HECTD1CD 
cannot ubiquitinate catalytic dead GST-HECTD1CD (C2579A or C2579G). Therefore, the observed 
autoubiquitination of GST-HECTD1WT occurs in cis. D) In vitro autoubiquitination carried out as in A 
using GST-HECTD1CD and UBE2D1, for 3 hrs at 30ºC, but using Konly ubiquitin mutants (i.e., only 
the indicated lysine residue has not been mutated to arginine). In order to differentiate between multi-
monoubiquitination events and polyubiquitination, UbMet and UbK0 were used as controls. Additional 
control samples included a no E1, no E2 or no E3 reactions. Reactions were stopped as in A) and 
analysed by western blotting using an anti-ubiquitin antibody. E) In vitro autoubiquitination carried 
out as in A) at 30ºC for 3 hrs, using GST-HECTD1CD, UBE2D1, wild-type ubiquitin or the indicated 
UbK/R ubiquitin mutants (i.e., only the indicated lysine is mutated to arginine). Reactions were stopped 

















Figure 5. HECTD1 assembles polyubiquitin chains containing K29 and K48 linkages. 
A) Time-course UbiCREST assays were performed on polyubiquitinated GST-HECTD1CD (55,56). 
In vitro autoubiquitination were carried out using GST-HECTD1CD, ATP, UBE1, UBE2D1, ubiquitin 
K0 (in order to identify multi-monoubiquitination events, lane 1) or ubiquitin WT (Lanes 2-5). 
Following incubation for 3 hrs at 30ºC, reactions were terminated through the addition of 2 mU 
apyrase for 20 minutes prior to addition of TRABID AnkOTU (2.5 µM), TRABID OTU (2.5 µM), 
Cezanne (1 µM), OTUB1* (2 µM), OTUD3 (2 µM) or USP2 (1 µM) for 5 min, 30 min or 60 minutes. 
UbiCREST reactions were terminated at the indicated time points by addition of 2X LDS/100mM 
DTT, resolved on a 4-12% SDS PAGE and analysed by western blotting using an anti-ubiquitin 
antibody. Note that remnant ubiquitin smears (AnkOTU, lanes 3-5) are shorter than smears obtained 
with UbWT (Lane 2) but longer than those in the multi-monoubiquitination control reaction (Lane 1). 
B) Double UbiCREST assay. In vitro autoubiquitination assays were carried out as in A but with His6-
HECTD1CD and incubated with either 1 µM of AnkOTU (Lane 3), 2 µM of OTUB1* (Lane 4) or 2 µM 
of USP2 for 1 hr at 30ºC (Lane 7), as indicated. AnkOTU and OTUB1* were also incubated at the 
same time and for 1 hr (Lane 5) or sequentially (i.e., AnkOTU was added for 5 min followed by 
OTUB1* for 1 hr, lane 6). Reactions were stopped by addition of in 2X LDS/100 mM and analysed 
by western blot using a ubiquitin (P4D1) antibody or an anti-UbK48-specific antibody. Note that the 
double UbiCREST does not lead to a reduction in the remnant ubiquitin signal that is obtained 
following AnkOTU treatment alone (Lane 3). Similar data was obtained with GST-HECTD1CD 
(Supplementary Figure 2D). C) In vitro autoubiquitination assays were carried out in the presence of 
ATP, UBE1, UBE2D1 and His6-HECTD1CD for 3 hrs at 30ºC. Ubiquitin wild type, UbK0 (i.e., control 
to show multi-monoubiquitination) or UbK29R were used, as indicated. Autoubiquitinated His6-
HECTD1CD obtained with UbWT was incubated with of 2.5 µM of TRABID AnkOTU for 1 hr at 30ºC, 
stopped by the addition of 2xLDS/100mM DTT and analysed by western blotting using an anti-
ubiquitin antibody. D) GST pulldown of His6-HECTD1CD either unmodified (Lanes 1, 6, 11), or 
modified with multi-monoubiquitination (Lanes 2, 7, 12), short chains (Lanes 3, 8, 12), or long chains 
(Lanes 4, 9, 14). Reactions showing remnant chains, which remain following TRABID AnkOTU 
treatment (Lanes 5, 10, 15), are also shown. GST pulldown was carried out as previously described 
(26). Briefly, GST or GST-TRABIDNZF 1-3 were coupled to glutathione magnetic beads for 1 hr at RT. 
Beads were washed in Pulldown buffer + BSA and then added to each of the in vitro ubiquitin 
reactions. Following overnight incubation on at 4ºC beads were washed with pulldown buffer five 
times. Beads were finally resuspended in 2X LDS/100 mM samples buffer and analysed by western 
blotting using an anti-ubiquitin antibody and also by silver stain to monitor protein loading 
(Supplementary Fig 3). Autoubiquitination assays shown in E) were analysed by Ubiquitin-AQUA 
proteomics for UbWT (F), UbWT followed by TRABID AnkOTU incubation (G), or UbK29R (H) 
















Figure 6. UBE3C and HECTD1 assemble K29/K48-linked ubiquitin chains of different 
topology. 
A) In vitro autoubiquitination assays were carried out with GST-HECTD1CD and GST-UBE3CCD as 
in Fig 4. Following incubation for 3 hrs at 30ºC, reactions were terminated through the addition of 2 
mU apyrase for 20 minutes prior to addition of TRABID AnkOTU (1 µM) or the K48-specific DUB 
OTUB1* (2 µM). Reactions were analysed by western blotting using an anti-ubiquitin (Top panel) or 
a UbK48-specific antibody (Lower panel). Note that as in Fig 5, remnant ubiquitin smears were 
observed for HECTD1 (Lane 3 vs. lane 2 & 1) following AnkOTU treatment, but not for UBE3C (Lane 
7 vs. 6 & 5). Free ubiquitin chains (Ub2 and Ub3) were also detected following AnkOTU treatment 
of UBE3C polyubiquitinated species. Incubation of autoubiquitination reactions with OTUB1* had a 
more dramatic effect for UBE3C which resulted in a ubiquitin smear similar to that obtained with UbK0 
and which indicates multi-monoubiquitination (Lane 8 vs. 6). In contrast, OTUB1* had a more modest 
effect on the autoubiquitination smear produced with either GST-HECTD1CD (Lane 4 vs. 2) or His6-
HECTD1CD (Supplementary Fig 2C). Similar data was obtained when analysing reactions with LI-
COR IRDyeÒ antibodies (Supplementary Fig 5C). Probing reactions with an anti-UbK48-specific 
antibody, revealed that AnkOTU treatment released free UbK48-linked ubiquitin chains, which were 
readily detected for UBE3C (Lower panel, lane 7 vs. 3). In contrast, treatment with OTUB1* yielded 
virtually no such free chains, in line with its K48 DUB activity (Lane 8 vs. 7). To establish whether 
the ubiquitin chains assembled through K29 and K48 had the same topology, we expressed and 
purified a UbK29/K48 only mutant in E.coli, and carried out in vitro autoubiquitination using either GST-
UBE3CCD (B) or GST-HECTD1CD (C). Note the ability for UBE3C to assemble long chains 
irrespective of whether UbWT or the UbK29only or UbK48only is used (Lanes 6 & 7 vs. 5). In contrast, 
HECTD1 could only assemble long chains in the presence of ubiquitin with both K29 and K48 
available (Lanes 8 & 5 vs. 7 & 6). D) To further establish that these represent branched rather than 
mixed chains, we repeated the reactions shown in C alongside a reaction containing both UbK29only 
and UbK48only proteins. This reaction has the potential to form heterotypic, but not branched, linkages. 
However, the chains assembled were comparable to those obtained with either of the UbK29only and 


















Figure 7. Ubiquitin chains modifying full-length endogenous HECTD1 are processed by 
TRABID DUB activity 
A) Catalytic dead TRABID (3xFLAG TRABIDC443S) was transiently overexpressed in HEK293T cells 
in order to trap polyubiquitinated endogenous HECTD1 (i.e., HECTD1HMW species). Following 
immunoprecipitation with FLAGÒ M2 beads, beads were either untreated (right panel, lane 1) or 
treated with 1 µM of TRABID AnkOTU (right panel, lane 2), or 2 µM of OTUB1* (right panel, lane 3). 
Reactions were stopped by addition of 2X LDS/100 mM DTT and analysed by western blot with the 
indicated antibodies. A higher exposure of the membrane is shown to facilitate the visualisation of 
HECTD1HMW species. TRABID DUB activity reduces HECTD1HMW species as well as the overall level 
of trapped polyubiquitin chains (Lane 2 vs. 1). In contrast, OTUB1* treatment has minimal effect on 
HECTD1HMW (IP HECTD1/WB Anti-HECTD1, lane 3 vs.1) or on trapped polyubiquitin chains (IP 
HECTD1/WB Anti-Ubiquitin, lane 3 vs. 1). B)  In vitro autoubiquitination assay using HA-FL-mouse-
Hectd1WT or catalytically dead (HA-FL-mouse-Hectd12587G). HA-FL-mHectd1WT or HA-FL-
mHectd1C2587G were transiently expressed in HEK293ET cells, immunoprecipitated using Pierce anti-
HA magnetic beads, eluted with an HA peptide, and used in autoubiquitination assays. Similar to the 
data obtained with GST-HECTD1CD, UbK29R does not support the full ligase activity of full-length 
mouse Hectd1 (Lane 3 vs. 2). Furthermore, chains produced with UbWT are readily processed by 
TRABID AnkOTU (Lane 4 vs. 2). HA-FL-mHectd1C2587G was used as control and showed no 

















Figure 8. TRABID stabilises HECTD1 protein levels.  
A) HEK293ET were transiently transfected with 20 pmol of the indicated siRNA (TRABID 
SMARTpool siRNA, SMARTpool individual #6, #7, #8, #9, or individual siRNA from previous studies, 
as indicated) (32,97). A non-targeting (NT) siRNA and HECTD1 siRNA were used as controls. Cell 
lysates were analysed by western blot and probed for endogenous HECTD1. The housekeeping 
protein b-Actin and total b-Catenin were used as controls. CRISPR/Cas9 TRABID KO clones (exon 
1 and 5 targeted) were analysed for HECTD1 protein levels in HEK293T (B) and MDCK cells (C). 
D) Loss of HECTD1 protein levels upon TRABID depletion in TRABID KO HEK293T cells is rescued 
following the stable re-expression of pEGFP- full-length TRABID, but not an empty pEGFP-Ev. 
GSK3b and b-Actin were used as loading controls. E) Mouse gut epithelia were analysed for Hectd1 
expression in three Trabid-/-, or wild type C57 mouse littermates. E-cadherin and Gsk3b were used 
as loading controls. F) The effect of Trabid depletion on Hectd1 levels was also observed in Liver 
and spleen tissues of those animals. G) Cycloheximide chase in HEK293ET cells transfected with 
either a non-targeting siRNA or TRABID SMARTpool siRNA for 72hrs followed by CHX addition (10 
µg/ml). Samples were collected at the indicated time points post CHX addition and analysed by 
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